Melane Sampson, Author at BioTuesdays

Developments

FDA certifies LSL’s ophthalmic ointment manufacturing for U.S. market

LSL Pharma (TSXV: LSL) has announced that the FDA has certified the ophthalmic ointment manufacturing operations of its subsidiary, Steri-Med Pharma, clearing the company to commercialize ophthalmic ointment products in...

January 28, 2026

Developments

Omeros launches first commercial sales of YARTEMLEA for TA-TMA

Omeros (NASDAQ: OMER) has announced that it has completed its first commercial shipments of YARTEMLEA to distributors for the treatment of adult and pediatric patients with stem cell transplant-associated thrombotic...

January 27, 2026

Developments

Ernexa chosen as one of ten for JETRO acceleration program

Ernexa Therapeutics (NASDAQ: ERNA) has announced it was selected as one of only ten global companies to participate in the prestigious Japan Entry Acceleration Program (JEAP) by the Japan External Trade Organization...

January 27, 2026

Developments

Pluri completes first phase of placenta-derived biomaterials program

Pluri (NASDAQ, TASE: PLUR) has announced the completion of the first phase of its program with closely held Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix- based...

January 22, 2026

Developments

Hoth reports positive interim results from trial of HT-001 in cancer patients

Hoth Therapeutics (NASDAQ: HOTH) has announced 100% clinical response and approximately 50% reduction in disease severity in the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 clinical trial evaluating...

January 22, 2026

Executive Moves

Zura names Dr. Sandeep Kulkarni as CEO

Zura Bio (NASDAQ: ZURA) has appointed Sandeep Kulkarni, MD, as chief executive officer (CEO), effective today. Dr. Kulkarni will continue to serve as a director of Zura. He succeeds Kim Davis, JD, who has served as...

January 21, 2026

Developments

Actuate to advance Elraglusib tablet to Phase 1/2 program in refractory cancers

Actuate Therapeutics (NASDAQ: ACTU) has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer. According to Actuate, the goal of...

January 21, 2026

Feature

First Ascent changing the cancer care narrative with functional precision medicine

Closely held First Ascent Biomedical is working to redefine how oncologists select therapies by pairing genomics with a proprietary live-cell testing platform that evaluates how an individual patient’s cancer responds...

January 20, 2026

Developments

BioNxt reports superior bioavailability of cladribine sublingual ODF

BioNxt Solutions (CSE: BNXT; OTCQB: BNXTF; FSE: BXT) has announced that it has completed a large-mass porcine comparative pharmacokinetic study and received preliminary results evaluating the absorption of cladribine...

January 19, 2026

Executive Moves

Arch names Dr. Patrick Vink as chairman of BOD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced the appointment of Dr. Patrick Vink as chairman of the company’s board of directors (BOD), effective January 15, 2026. Dr. Vink, MD, MBA, has been an advisor to...

January 16, 2026

Author - Melane Sampson

FDA certifies LSL’s ophthalmic ointment manufacturing for U.S. market

Omeros launches first commercial sales of YARTEMLEA for TA-TMA

Ernexa chosen as one of ten for JETRO acceleration program

Pluri completes first phase of placenta-derived biomaterials program

Hoth reports positive interim results from trial of HT-001 in cancer patients

Zura names Dr. Sandeep Kulkarni as CEO

Actuate to advance Elraglusib tablet to Phase 1/2 program in refractory cancers

First Ascent changing the cancer care narrative with functional precision medicine

BioNxt reports superior bioavailability of cladribine sublingual ODF

Arch names Dr. Patrick Vink as chairman of BOD

Subscribe